Drug-drug Interactions Between COVID-19 Treatments and Antipsychotics Drugs: Integrated Evidence from 4 Databases and a Systematic Review

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2021 Jan 7

PMID 33410987

Citations 23

Authors

Beatriz Oda Plasencia-Garcia

Gonzalo Rodriguez-Menendez

Maria Isabel Rico-Rangel

Ana Rubio-Garcia

Jaime Torello-Iserte

Benedicto Crespo-Facorro

Affiliations

Soon will be listed here.

Abstract

Rationale: Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics should consider eventual drug-drug interactions OBJECTIVE: To systematically review evidence-based available on drug-drug interactions between COVID-19 treatments and antipsychotics.

Evidence Review: Three databases were consulted: Lexicomp® Drug Interactions, Micromedex® Solutions Drugs Interactions, and Liverpool© Drug Interaction Group for COVID-19 therapies. To acquire more information on QT prolongation and Torsade de Pointes (TdP), the CredibleMeds® QTDrugs List was searched. The authors made a recommendation agreed to by consensus. Additionally, a systematic review of drug-drug interactions between antipsychotics and COVID-19 treatment was conducted.

Results: The main interactions between COVID-19 drugs and antipsychotics are the risk of QT-prolongation and TdP, and cytochromes P450 interactions. Remdesivir, baricinitib, and anakinra can be used concomitantly with antipsychotics without risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib). Favipiravir only needs caution with chlorpromazine and quetiapine. Tocilizumab is rather safe to use in combination with antipsychotics. The most demanding COVID-19 treatments for coadministration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir because of the risk of QT prolongation and TdP and cytochromes interactions. The systematic review provides highly probable drug interaction between lopinavir/ritonavir plus quetiapine and ritonavir/indinavir plus risperidone.

Conclusions: Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety.

Citing Articles

Acute Schizophrenia-like Psychotic Disorder Against the Background of COVID-19.

Bravve L, Kaydan M, Kostyuk G Medicina (Kaunas). 2025; 61(2).

PMID: 40005415 PMC: 11857278. DOI: 10.3390/medicina61020298.

Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence.

Rezabakhsh A, Mojtahedi F, Tahsini Tekantapeh S, Mahmoodpoor A, Ala A, Soleimanpour H Arch Acad Emerg Med. 2024; 12(1):e47.

PMID: 38994467 PMC: 11239185. DOI: 10.22037/aaem.v12i1.2217.

Drug-Drug Interactions in Patients with Acute Respiratory Distress Syndrome.

Bischof T, Schaller C, Buchtele N, Staudinger T, Ullrich R, Kraft F Pharmaceutics. 2024; 16(3).

PMID: 38543197 PMC: 10974914. DOI: 10.3390/pharmaceutics16030303.

Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study.

Boppana U, Leonard T, Jolayemi A, Ansari M, Salib A Cureus. 2024; 15(12):e50469.

PMID: 38222143 PMC: 10786447. DOI: 10.7759/cureus.50469.

Drug-drug Interaction between Psychotropic Medications and Medications Used in COVID-19: Comparison of Online Databases.

Chatterjee S, Kar S, Prakash A, Bansal T, Singh G Clin Psychopharmacol Neurosci. 2023; 21(3):534-543.

PMID: 37424421 PMC: 10335911. DOI: 10.9758/cpn.22.1014.

References

Acciavatti T, Martinotti G, Corbo M, Cinosi E, Lupi M, Ricci F . Psychotropic drugs and ventricular repolarisation: The effects on QT interval, T-peak to T-end interval and QT dispersion. J Psychopharmacol. 2017; 31(4):453-460. DOI: 10.1177/0269881116684337. View

Aitken A, Morgan E . Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007; 35(9):1687-93. PMC: 2171046. DOI: 10.1124/dmd.107.015511. View

Aung G, OBrien J, Tien P, Kawamoto L . Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010; 44(11):1850-4. DOI: 10.1345/aph.1P139. View

Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M . Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(4):e208857. DOI: 10.1001/jamanetworkopen.2020.8857. View

Chao S, Maibach H . Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol. 2005; 6(2):105-11. DOI: 10.2165/00128071-200506020-00005. View

Conley R, Kelly D . Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull. 2007; 40(1):77-97. View

Ely E, Gautam S, Margolin R, Francis J, May L, Speroff T . The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2002; 27(12):1892-900. PMC: 7095464. DOI: 10.1007/s00134-001-1132-2. View

Wesley Ely E, Shintani A, Truman B, Speroff T, Gordon S, Harrell Jr F . Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004; 291(14):1753-62. DOI: 10.1001/jama.291.14.1753. View

Ernest 2nd C, Hall S, Jones D . Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2004; 312(2):583-91. DOI: 10.1124/jpet.104.075416. View

10.

Etchegoyen C, Keller G, Mrad S, Cheng S, Di Girolamo G . Drug-induced QT Interval Prolongation in the Intensive Care Unit. Curr Clin Pharmacol. 2018; 12(4):210-222. DOI: 10.2174/1574884713666180223123947. View

11.

Fihn S, Perencevich E, Bradley S . Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019. JAMA Netw Open. 2020; 3(4):e209035. DOI: 10.1001/jamanetworkopen.2020.9035. View

12.

Foisy M, Yakiwchuk E, Hughes C . Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008; 42(7):1048-59. DOI: 10.1345/aph.1K615. View

13.

Gareri P, De Fazio P, Manfredi V, De Sarro G . Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol. 2013; 34(1):109-23. DOI: 10.1097/JCP.0b013e3182a6096e. View

14.

Geraci M, McCoy S, Crum P, Patel R . Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction. Int J Emerg Med. 2010; 3(2):81-4. PMC: 2885261. DOI: 10.1007/s12245-010-0175-y. View

15.

Guzik T, Mohiddin S, Dimarco A, Patel V, Savvatis K, Marelli-Berg F . COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; 116(10):1666-1687. PMC: 7197627. DOI: 10.1093/cvr/cvaa106. View

16.

Haeusler I, Chan X, Guerin P, White N . The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med. 2018; 16(1):200. PMC: 6220451. DOI: 10.1186/s12916-018-1188-2. View

17.

Horn J, Hansten P, Chan L . Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41(4):674-80. DOI: 10.1345/aph.1H423. View

18.

Hsu A, Granneman G, Witt G, Locke C, Denissen J, Molla A . Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997; 41(5):898-905. PMC: 163822. DOI: 10.1128/AAC.41.5.898. View

19.

Jin B, Liu H . Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis. J Neurol. 2019; 266(10):2363-2375. DOI: 10.1007/s00415-019-09200-8. View

20.

Jover F, Cuadrado J, Andreu L, Merino J . Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002; 25(5):251-3. DOI: 10.1097/00002826-200209000-00004. View